Erlotinib

Drug Profile

Erlotinib

Alternative Names: CP-358774; CP-358774-01; Erlotinib hydrochloride; NSC-718781; OSI-774; R-1415; RG-1415; RO-508231; Ro50-8231; Tarceva

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Astellas Pharma; Chugai Pharmaceutical; Finnish Lung Cancer Group; Genentech; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; OSI Pharmaceuticals; Polyphenon Pharma; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Alkynes; Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Pancreatic cancer
  • Phase III Ependymoma; Head and neck cancer
  • Phase II Bladder cancer; Brain metastases; Glioblastoma; Gynaecological cancer; Neuroendocrine tumours; Squamous cell cancer
  • Phase I/II Colorectal cancer; Myelodysplastic syndromes
  • Phase I Breast cancer; Solid tumours
  • Preclinical Cancer metastases
  • No development reported Anaplastic astrocytoma; Bronchiolo-alveolar adenocarcinoma
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 02 Jun 2017 Interim efficacy data from a phase I trial in Non small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Interim efficacy and adverse events data from the phase I/II EViCT trial in Colorectal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 06 Mar 2017 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02942095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top